Beaumont Financial Advisors LLC Buys 810 Shares of Stryker Co. (NYSE:SYK)

Beaumont Financial Advisors LLC boosted its stake in Stryker Co. (NYSE:SYK) by 40.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,837 shares of the medical technology company’s stock after purchasing an additional 810 shares during the period. Beaumont Financial Advisors LLC’s holdings in Stryker were worth $1,021,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. AE Wealth Management LLC increased its stake in shares of Stryker by 101.8% in the second quarter. AE Wealth Management LLC now owns 3,414 shares of the medical technology company’s stock valued at $1,162,000 after buying an additional 1,722 shares during the period. Public Sector Pension Investment Board boosted its stake in shares of Stryker by 79.0% in the 2nd quarter. Public Sector Pension Investment Board now owns 12,579 shares of the medical technology company’s stock valued at $4,280,000 after purchasing an additional 5,553 shares during the last quarter. Evergreen Capital Management LLC increased its position in shares of Stryker by 5.2% during the second quarter. Evergreen Capital Management LLC now owns 4,259 shares of the medical technology company’s stock worth $1,453,000 after buying an additional 212 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in Stryker by 60.0% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 65,552 shares of the medical technology company’s stock worth $22,304,000 after buying an additional 24,589 shares during the last quarter. Finally, Insigneo Advisory Services LLC boosted its position in Stryker by 31.9% during the second quarter. Insigneo Advisory Services LLC now owns 2,150 shares of the medical technology company’s stock valued at $679,000 after acquiring an additional 520 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

SYK has been the subject of several research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $420.00 price objective (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Barclays lifted their target price on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $425.00 price target on shares of Stryker in a research note on Tuesday, January 7th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $405.80.

Stryker Stock Down 1.4 %

Stryker stock opened at $390.31 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $148.79 billion, a P/E ratio of 41.83, a P/E/G ratio of 2.63 and a beta of 0.95. The firm has a 50 day moving average price of $375.78 and a 200-day moving average price of $359.94. Stryker Co. has a twelve month low of $307.23 and a twelve month high of $398.20.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period last year, the business posted $2.46 earnings per share. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, equities analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is presently 36.01%.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 5.50% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.